Vaishali J. Patel
Consumer Safety Officer / Investigator
ORA Denver District
Aseptic processing and contamination control specialist with 96 site inspections across 6 countries — co-investigates with Boyd and Shields on high-impact sterile manufacturing inspections in India.
Inspection Approach
How Vaishali Inspects
Patel focuses on the operational integrity of aseptic manufacturing, with particular attention to cross-contamination prevention between production areas and facilities. Her inspection methodology examines the full contamination control lifecycle — from facility design and environmental monitoring through process validation and complaint management.
Her co-investigation with Justin A. Boyd and Anastasia M. Shields at EUGIA Pharma Specialities in India resulted in a 7-observation 483 and subsequent warning letter, where the team identified inadequate containment controls, deficient operator practices in aseptic areas, and failures in cleaning and environmental monitoring. The fact that she co-investigates with two of the most well-known sterile manufacturing specialists in FDA suggests she operates at a similarly high level.
Patel's approach to complaints and CAPA is notably thorough — she traces quality system responsiveness from initial complaint through investigation, root cause identification, and corrective action effectiveness. She evaluates whether failure investigations identify genuine root causes rather than speculative "most probable" hypotheses.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
EUGIA Pharma Specialities Limited (Unit IV)
- Inadequate containment controls to prevent cross-contamination between facilities
- Inadequate operator practices in aseptic processing areas
- Deficient cleaning practices and environmental monitoring in aseptic areas
- Failure to establish required controls before introducing new manufacturing operations
- Inadequate failure investigations — root causes not scientifically established
- 7-observation Form 483 leading to Warning Letter 681905 (August 2024)
EUGIA Pharma Specialities Limited (Unit III)
- Data accuracy failures for production and process simulation records
- Failure to prevent microbiological contamination of sterile products
- Unauthorised changes to master production records via computerised systems
- Deficient laboratory controls and test procedures — related to Warning Letter 681905
Xellia Pharmaceuticals USA LLC
- Injectable/sterile drug manufacturing deficiencies identified during routine inspection
Pre-Inspection Preparation
How to Prepare
- 1 Ensure all aseptic processing areas have validated environmental monitoring programmes with trending data readily available.
- 2 Verify media fill programmes are current and cover all aseptic filling configurations used in commercial manufacturing.
- 3 Review containment controls between manufacturing areas — especially at multi-product or multi-facility sites.
- 4 Audit complaint handling procedures to ensure investigations are thorough, timely, and documented with root cause CAPA.
- 5 Confirm all process validations are current and scientifically justified for the products being manufactured.
- 6 Prepare documentation showing cross-contamination risk assessments between shared equipment and facilities.
- 7 Ensure environmental monitoring excursion investigations include impact assessments on all batches produced during the excursion.
- 8 Verify cleaning validation covers worst-case scenarios for shared equipment in multi-product environments.
- 9 Review operator qualification records for aseptic technique — ensure all personnel are currently qualified.
- 10 Have documentation ready showing controls established before any new manufacturing operations were introduced.
- 11 Ensure failure investigations identify genuine root causes with supporting data — not just "most probable" hypotheses.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Vaishali J. Patel — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
